Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman Sells 4,483 Shares

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 4,483 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $12.01, for a total value of $53,840.83. Following the transaction, the chief financial officer now owns 159,626 shares of the company’s stock, valued at approximately $1,917,108.26. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Robert Thomas Freeman also recently made the following trade(s):

• On Thursday, October 31st, Robert Thomas Freeman sold 36,197 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.04, for a total transaction of $435,811.88.
• On Monday, October 14th, Robert Thomas Freeman sold 30,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $11.50, for a total value of $350,750.00.
• On Tuesday, October 8th, Robert Thomas Freeman sold 39,320 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.04, for a total transaction of $473,412.80.
• On Tuesday, October 1st, Robert Thomas Freeman sold 21,375 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.66, for a total value of $227,857.50.
• On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.00, for a total value of $174,000.00.
• On Wednesday, September 11th, Robert Thomas Freeman sold 8,561 shares of Alignment Healthcare stock. The stock was sold at an average price of $10.01, for a total transaction of $85,695.61.
• On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total value of $16,500.00.

Alignment Healthcare Trading Up 5.7 %

NASDAQ ALHC opened at $12.40 on Friday. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.70. The firm has a 50-day moving average price of $10.74 and a 200 day moving average price of $8.73. Alignment Healthcare, Inc. has a 52-week low of $4.46 and a 52-week high of $12.44. The stock has a market capitalization of $2.37 billion, a P/E ratio of -16.10 and a beta of 1.47.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). Alignment Healthcare had a negative net margin of 6.85% and a negative return on equity of 101.10%. The firm had revenue of $692.43 million during the quarter, compared to analysts’ expectations of $662.11 million. During the same quarter last year, the business earned ($0.19) earnings per share. The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. Equities research analysts expect that Alignment Healthcare, Inc. will post -0.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ALHC shares. UBS Group increased their price objective on Alignment Healthcare from $9.00 to $12.00 and gave the company a “neutral” rating in a report on Wednesday. Barclays increased their price target on shares of Alignment Healthcare from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday. TD Cowen raised their price objective on Alignment Healthcare from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Piper Sandler reissued an “overweight” rating and issued a $10.00 price target (up previously from $8.00) on shares of Alignment Healthcare in a research note on Tuesday, August 6th. Finally, Stifel Nicolaus upped their price target on shares of Alignment Healthcare from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $10.33.

Hedge Funds Weigh In On Alignment Healthcare

Several hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Alignment Healthcare by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 39,570 shares of the company’s stock worth $196,000 after purchasing an additional 3,334 shares during the period. Principal Financial Group Inc. purchased a new stake in Alignment Healthcare in the first quarter valued at approximately $57,000. Blue Trust Inc. increased its holdings in shares of Alignment Healthcare by 47.4% during the 1st quarter. Blue Trust Inc. now owns 256,452 shares of the company’s stock worth $1,272,000 after buying an additional 82,476 shares during the last quarter. Vanguard Group Inc. increased its stake in Alignment Healthcare by 1.0% during the first quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock worth $45,828,000 after acquiring an additional 93,262 shares during the last quarter. Finally, Hood River Capital Management LLC raised its holdings in shares of Alignment Healthcare by 49.6% in the 1st quarter. Hood River Capital Management LLC now owns 2,920,836 shares of the company’s stock worth $14,487,000 after purchasing an additional 968,637 shares during the period. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.